Indications and uses
Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is indicated for procedures requiring a rapid and short-acting topical ophthalmic anesthetic.
Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is indicated for procedures requiring a rapid and short-acting topical ophthalmic anesthetic.
One drop topically in the eye(s) as needed.
Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is supplied as a sterile, aqueous, topical ophthalmic solution in a low-density polyethylene plastic dropper bottle with a low-density polyethylene dropper tip and white polypropylene cap in the following sizes: NDC 82260-920-15 15 mL in a 15 mL Bottle NDC 82260-920-05 5 mL in a 7.5 mL Bottle After opening, this product can be used until the expir...
Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is indicated for procedures requiring a rapid and short-acting topical ophthalmic anesthetic.
One drop topically in the eye(s) as needed.
Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is a clear, colorless, ophthalmic solution containing 0.5% w/v tetracaine hydrochloride equivalent to tetracaine 0.44% w/v.
Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% should not be used in patients with a history of hypersensitivity to any component of this preparation.
Not for injection or intraocular use. Do not use intracamerally because use of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% may lead to damage of the corneal endothelial cells.
Prolonged use or abuse may lead to corneal epithelial toxicity and may manifest as epithelial defects which may progress to permanent corneal damage.
Patients should not touch the eye for at least 10-20 minutes after using anesthetic as accidental injuries can occur due to insensitivity of the eye.
Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is indicated for administration under the direct supervision of a healthcare provider. Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is not intended for patient self-administration [see Warnings and Precautions (5.2)] .
The following serious ocular adverse reactions are described elsewhere in the labeling:
The following adverse reactions have been identified following use of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5%. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Ocular Adverse Reactions
Transient stinging, burning, and conjunctival redness, eye irritation, eye pain, ocular discomfort.
Risk Summary
There are no adequate and well-controlled studies with Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% in pregnant women. Animal developmental and reproductive toxicity studies with tetracaine hydrochloride have not been reported in the published literature.
Risk Summary
There are no data to assess whether Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is excreted in human milk or to assess its effects on milk production/excretion. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% and any potential adverse effects on the breastfed child from Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5%.
No human data on the effect of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% on fertility are available.
Safety of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% in the pediatric population has been demonstrated in clinical trials. Efficacy of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% for use in pediatric patients has been extrapolated from adequate and well-controlled clinical trials in the adult population.
No overall differences in safety or effectiveness of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% have been observed between elderly and younger patients.
Prolonged use of a topical ocular anesthetic including Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% may produce permanent corneal opacification and ulceration with accompanying visual loss.
Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is a sterile, clear, colorless, topical local anesthetic for ophthalmic use only containing tetracaine hydrochloride as the active pharmaceutical ingredient.
Tetracaine hydrochloride is chemically designated as benzoic acid, 4-(butylamino)-, 2-(dimethylamino) ethyl ester, monohydrochloride. Its chemical formula is C 15H 24N 2O 2● HCl and it is represented by the chemical structure:

Tetracaine hydrochloride is a fine, white, crystalline, odorless powder with a molecular weight of 300.83.
Active ingredient:tetracaine hydrochloride 0.5% w/v (equivalent to 0.44% w/v tetracaine)
Preservative:chlorobutanol 0.4%
Inactive ingredients:boric acid, edetate disodium dihydrate, potassium chloride, water for injection. Sodium hydroxide and/or hydrochloric acid may be added to adjust pH (3.7 – 6.0).
Tetracaine blocks sodium ion channels required for the initiation and conduction of neuronal impulses thereby affecting local anesthesia.
The systemic exposure to tetracaine following topical ocular administration of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% has not been studied. Tetracaine hydrochloride is metabolized by plasma pseudocholinesterases and nonspecific esterases in ocular tissues.
Studies to assess the genotoxicity of tetracaine hydrochloride have not been reported in the published literature. Long-term animal studies have not been conducted to evaluate the carcinogenic potential of tetracaine hydrochloride. Animal studies to assess the effects of tetracaine hydrochloride on fertility have not been reported in the published literature.
Topical administration of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% results in localized temporary anesthesia. The maximum effect is achieved within 10–20 seconds after instillation, with efficacy lasting 10–20 minutes. Duration of effect can be extended with repeated dosing [see Warnings and Precautions (5.2)and Overdosage (10)] .
Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is supplied as a sterile, aqueous, topical ophthalmic solution in a low-density polyethylene plastic dropper bottle with a low-density polyethylene dropper tip and white polypropylene cap in the following sizes:
After opening, this product can be used until the expiration date stamped on the bottle.
Storage:Store at 15°C to 25°C (59°F to 77°F). Protect from light. Do not use if solution contains crystals, cloudy, or discolored.
Eye Care Precaution
Do not touch the dropper tip to any surface as this may contaminate the solution.
Advise patients that, due to the effect of the anesthetic, their eyes will be insensitive for up to 20 minutes and that care should be taken to avoid accidental injuries.
Distributed by:
Bausch & Lomb Americas Inc.
Bridgewater, NJ 08807 USA
Manufactured by:
Bausch & Lomb Incorporated
Tampa, FL 33637 USA
© 2022 Bausch & Lomb Incorporated or its affiliates
9780400 (Folded)
9780500 (Flat)
| Class | Version | Type | Effective |
|---|---|---|---|
| TETRACAINE Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 82260-920-05 | Tetracaine Hydrochloride | 5 mL in 1 BOTTLE, DROPPER | SOLUTION/ DROPS | 5 | 4 | |
| 82260-920-05 | Tetracaine Hydrochloride | 1 in 1 CARTON | SOLUTION/ DROPS | 1 | 4 | |
| 82260-920-15 | Tetracaine Hydrochloride | 15 mL in 1 BOTTLE, DROPPER | SOLUTION/ DROPS | 15 | 4 | |
| 82260-920-15 | Tetracaine Hydrochloride | 1 in 1 CARTON | SOLUTION/ DROPS | 1 | 4 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 82260-920-05 | ML - Milliliter | 82260-920 | 4e8715ca-5113-467e-a4f2-8040fa61bc65 | 1 | 2025-10-14 |
| 82260-920-15 | ML - Milliliter | 82260-920 | f8e6c65f-1b0d-485f-ba22-3b2410b4267b | 1 | 2025-10-14 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 82260-920 | 82260-920-05, 82260-920-15 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| CHLOROBUTANOL | HM4YQM8WRC | IACT |
| BORIC ACID | R57ZHV85D4 | IACT |
| POTASSIUM CHLORIDE | 660YQ98I10 | IACT |
| EDETATE DISODIUM | 7FLD91C86K | IACT |
| WATER | 059QF0KO0R | IACT |
| SODIUM HYDROXIDE | 55X04QC32I | IACT |
| HYDROCHLORIC ACID | QTT17582CB | IACT |
| TETRACAINE HYDROCHLORIDE | 5NF5D4OPCI | ACTIB |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N210821-001 | TETRACAINE HYDROCHLORIDE | TETRACAINE HYDROCHLORIDE | 0.5% | SOLUTION / OPHTHALMIC | AB1 | RLD, RS | 2019-03-12 |
| Application-product | TE code |
|---|---|
| N210821-001 | AB1 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N210821-001 | TETRACAINE HYDROCHLORIDE | 0.5% | SOLUTION / OPHTHALMIC | AB1 | RLD, RS | 2019-03-12 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | N210821-001 | TETRACAINE HYDROCHLORIDE | 0.5% | SOLUTION / OPHTHALMIC | AB1 | RLD, RS | 2019-03-12 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | N210821-001 | TETRACAINE HYDROCHLORIDE | 0.5% | SOLUTION / OPHTHALMIC | AB1 | RLD, RS | 2019-03-12 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N210821-001 | TETRACAINE HYDROCHLORIDE | 0.5% | SOLUTION / OPHTHALMIC | AB1 | RLD, RS | 2019-03-12 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | N210821-001 | TETRACAINE HYDROCHLORIDE | 0.5% | SOLUTION / OPHTHALMIC | AB1 | RLD, RS | 2019-03-12 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N210821-001 | TETRACAINE HYDROCHLORIDE | 0.5% | SOLUTION / OPHTHALMIC | AB1 | RLD, RS | 2019-03-12 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N210821-001 | TETRACAINE HYDROCHLORIDE | 0.5% | SOLUTION / OPHTHALMIC | AB1 | RLD, RS | 2019-03-12 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N210821-001 | TETRACAINE HYDROCHLORIDE | 0.5% | SOLUTION / OPHTHALMIC | AB1 | RLD, RS | 2019-03-12 | 03ed91905a0d… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N210821-001 | TETRACAINE HYDROCHLORIDE | 0.5% | SOLUTION / OPHTHALMIC | RLD, RS | 2019-03-12 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N210821-001 | TETRACAINE HYDROCHLORIDE | 0.5% | SOLUTION / OPHTHALMIC | RLD, RS | 2019-03-12 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N210821-001 | TETRACAINE HYDROCHLORIDE | 0.5% | SOLUTION / OPHTHALMIC | RLD, RS | 2019-03-12 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | N210821-001 | TETRACAINE HYDROCHLORIDE | 0.5% | SOLUTION / OPHTHALMIC | RLD, RS | 2019-03-12 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N210821-001 | TETRACAINE HYDROCHLORIDE | 0.5% | SOLUTION / OPHTHALMIC | RLD, RS | 2019-03-12 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N210821-001 | TETRACAINE HYDROCHLORIDE | 0.5% | SOLUTION / OPHTHALMIC | RLD, RS | 2019-03-12 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N210821-001 | TETRACAINE HYDROCHLORIDE | 0.5% | SOLUTION / OPHTHALMIC | RLD, RS | 2019-03-12 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | N210821-001 | TETRACAINE HYDROCHLORIDE | 0.5% | SOLUTION / OPHTHALMIC | RLD, RS | 2019-03-12 | 8072bd15b7f6… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N210821-001 | TETRACAINE HYDROCHLORIDE | 0.5% | SOLUTION / OPHTHALMIC | RLD, RS | 2019-03-12 | 5c6f7cd8ea54… | |
| 2022-04-08 23:34 UTC | 2022-04 | N210821-001 | TETRACAINE HYDROCHLORIDE | 0.5% | SOLUTION / OPHTHALMIC | RLD, RS | 2019-03-12 | 5d02ea3f76ae… | |
| 2022-04-04 05:41 UTC | 2022-04 | N210821-001 | TETRACAINE HYDROCHLORIDE | 0.5% | SOLUTION / OPHTHALMIC | RLD, RS | 2019-03-12 | 4b0b4de00fa7… | |
| 2019-12-13 00:20 UTC | 2019-12 | N210821-001 | TETRACAINE HYDROCHLORIDE | 0.5% | SOLUTION / OPHTHALMIC | 2019-03-12 | 74a2ff9319b5… | ||
| 2022-03-09 01:35 UTC | 2022-03 | N210821-001 | TETRACAINE HYDROCHLORIDE | 0.5% | SOLUTION / OPHTHALMIC | RLD, RS | 2019-03-12 | bb7c543d1eb4… | |
| 2021-12-28 21:50 UTC | 2021-12 | N210821-001 | TETRACAINE HYDROCHLORIDE | 0.5% | SOLUTION / OPHTHALMIC | RLD, RS | 2019-03-12 | 782e0a99824c… | |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | N210821-001 | TETRACAINE HYDROCHLORIDE | 0.5% | SOLUTION / OPHTHALMIC | RLD, RS | 2019-03-12 | 87673890dc5c… | |
| 2021-03-12 10:30 UTC | 2021-03 | N210821-001 | TETRACAINE HYDROCHLORIDE | 0.5% | SOLUTION / OPHTHALMIC | RLD, RS | 2019-03-12 | 5aa47cf7b7d7… | |
| 2020-12-22 03:56 UTC | 2020-12 | N210821-001 | TETRACAINE HYDROCHLORIDE | 0.5% | SOLUTION / OPHTHALMIC | RLD, RS | 2019-03-12 | 8869cabd3fbd… | |
| 2020-11-12 02:37 UTC | 2020-11 | N210821-001 | TETRACAINE HYDROCHLORIDE | 0.5% | SOLUTION / OPHTHALMIC | 2019-03-12 | c0c555d07b60… | ||
| 2019-12-14 00:12 UTC | 2019-12 | N210821-001 | TETRACAINE HYDROCHLORIDE | 0.5% | SOLUTION / OPHTHALMIC | 2019-03-12 | 3f01610625f2… | ||
| 2019-09-15 20:21 UTC | 2019-09 | N210821-001 | TETRACAINE HYDROCHLORIDE | 0.5% | SOLUTION / OPHTHALMIC | 2019-03-12 | b00525d2431f… | ||
| 2019-07-19 19:46 UTC | 2019-07 | N210821-001 | TETRACAINE HYDROCHLORIDE | 0.5% | SOLUTION / OPHTHALMIC | 2019-03-12 | ea99ee380514… | ||
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | N210821-001 | TETRACAINE HYDROCHLORIDE | 0.5% | SOLUTION / OPHTHALMIC | RLD, RS | 2019-03-12 | 6a51e52b5d6a… | |
| 2024-02-18 07:12 UTC | 2024-02 | N210821-001 | TETRACAINE HYDROCHLORIDE | 0.5% | SOLUTION / OPHTHALMIC | RLD, RS | 2019-03-12 | 1c564ffb4f44… | |
| 2023-12-20 04:57 UTC | 2023-12 | N210821-001 | TETRACAINE HYDROCHLORIDE | 0.5% | SOLUTION / OPHTHALMIC | RLD, RS | 2019-03-12 | ea1830bbd6c7… | |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | N210821-001 | TETRACAINE HYDROCHLORIDE | 0.5% | SOLUTION / OPHTHALMIC | RLD, RS | 2019-03-12 | a72a2bbeb626… | |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | N210821-001 | TETRACAINE HYDROCHLORIDE | 0.5% | SOLUTION / OPHTHALMIC | RLD, RS | 2019-03-12 | 9b2671bbb829… | |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | N210821-001 | TETRACAINE HYDROCHLORIDE | 0.5% | SOLUTION / OPHTHALMIC | RLD, RS | 2019-03-12 | a67488948f0b… | |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | N210821-001 | TETRACAINE HYDROCHLORIDE | 0.5% | SOLUTION / OPHTHALMIC | RLD, RS | 2019-03-12 | 3f0d92c62455… | |
| 2023-05-13 08:27 UTC | 2023-05 | N210821-001 | TETRACAINE HYDROCHLORIDE | 0.5% | SOLUTION / OPHTHALMIC | RLD, RS | 2019-03-12 | 053a50430f4f… | |
| 2023-01-26 05:58 UTC | 2023-01 | N210821-001 | TETRACAINE HYDROCHLORIDE | 0.5% | SOLUTION / OPHTHALMIC | RLD, RS | 2019-03-12 | 3bdfa0b2c4d7… | |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | N210821-001 | TETRACAINE HYDROCHLORIDE | 0.5% | SOLUTION / OPHTHALMIC | RLD, RS | 2019-03-12 | 3a93d1ddd44b… | |
| 2022-10-28 04:53 UTC | 2022-10 | N210821-001 | TETRACAINE HYDROCHLORIDE | 0.5% | SOLUTION / OPHTHALMIC | RLD, RS | 2019-03-12 | f41ea6bd6efb… |
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N210821-001 | AB1 | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | N210821-001 | AB1 | 1 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | N210821-001 | AB1 | 1 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N210821-001 | AB1 | 1 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | N210821-001 | AB1 | 1 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N210821-001 | AB1 | 1 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N210821-001 | AB1 | 1 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N210821-001 | AB1 | 1 | 03ed91905a0d… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | N210821-001 | AB1 | 1 | a50c72e98297… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Tetracaine Hydrochloride | TETRACAINE HYDROCHLORIDE | Bausch & Lomb Americas Inc. | f12d5944-0d6c-43ff-89fd-e0b5669e9b4a | 2026-02-07 | Warnings, Adverse reactions | 82260-920-15 82260-920-05 82260-920 82260092005 82260092015 4a468703-7613-0c8b-e063-6294a90a2f6e f12d5944-0d6c-43ff-89fd-e0b5669e9b4a |
Adverse event summaries are temporarily unavailable. Other product information remains available.